Lymph node response is the most widely used indication for adjuvant treatment in patients with breast cancer as it is generally recognised to be the best high risk indicator. About 40% of patients with lymph node metastases, however, are still alive five years after diagnosis,' which indicates that those with positive lymph nodes can be further subdivided into patients with favourable and unfavourable prognoses, respectively.
Several studies have tried to find additional prognostic factors for lymph node positive patients with breast cancer in either the primary tumour or lymph node metastases. The addition of tumour size and the mitotic activity index (MI) of the primary tumour to lymph -node response27 has been shown to improve prognostic prediction in lymph node positive patients. Maehle To our knowledge, no study has so far described the prognostic value of proliferation variables derived from lymph node metastases. The aim of this study, therefore, was to evaluate whether proliferative activity of distant breast cancer metastases could be predicted by the degree of proliferation in axillary lymph node metastases compared with classic and morphometric lymph node variables.
Methods
A total of 52 patients with invasive breast cancer metastatic to the axillary lymph nodes, diagnosed between 1971 and 1981, were included in this study. All patients were treated with radical or modified mastectomy. Postoperative regional radiotherapy was given in all cases, and none of the patients received any form of adjuvant systemic treatment. Mean age at the time of diagnosis was 57-3 years (range 27-84). The median follow up for all patients was 84 months (range 18-215), and the median follow up of the surviving patients was 121 months (range 59-215). Table 1 summarises the clinical data of the patients.
Lymph nodes were identified in the fresh axillary dissection preparation, fixed in neutral buffered formalin, and embedded in paraffin wax. Sections (4 jgm thick) were cut and stained with haematoxylin and eosin. All identified lymph nodes were reviewed and all lymph nodes containing metastatic breast cancer cells were further considered for all patients. The total number and percentage of lymph node metastases were registered. Patients had, on average, 6-1 positive lymph nodes (range 1-33). In total, 304 lymph node metastases were thus evaluated.
In all positive lymph nodes of each case the most cellular area containing the highest density of mitotic figures was chosen, excluding areas with necrosis and many non-malignant cells: an area of about 0 5 x 05 cm was marked. In this area mitotic counting and nuclear measurements were performed. Figure 2 shows the survival curves for these groups. In conclusion, proliferation variables obtained from axillary lymph node metastases of patients with breast cancer have prognostic value and could therefore predict the behaviour of distant metastases in such patients.
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